People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocular Therapeutix, Inc | — | Biotechnology | Series B | $81.0M | $1.5B | 2019 |
Daniel Bollag at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Bollag on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FARHAD KHOSRAVI | 1 | 14 |
| Richard Lindstrom | 1 | 13 |
| Alan Crane | 1 | 9 |
| Amarpreet Sawhney | 1 | 8 |
| Richard L Lindstrom | 1 | 8 |
| Brian Levy | 1 | 8 |
| James Garvey | 1 | 6 |
| Charles Warden | 1 | 5 |
| Steven Cagnetta | 1 | 5 |
| Daniel Myers | 1 | 2 |
| Charles A. Warden | 1 | 2 |
| Samuel Wu | 1 | 2 |
| Jaswinder Chadha | 1 | 2 |
| Bruce A. Peacock | 1 | 2 |
| Donald Notman | 1 | 2 |
| Michael Goldstein | 1 | 2 |
| W. James O'Shea | 1 | 2 |
| Bernard Haffey | 1 | 1 |
| Alan Crain | 1 | 1 |
| Jeffrey S. Heier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.